World

Guinea-Bissau has cancelled a controversial US-funded hepatitis B vaccine trial.

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 06/11/2026, 12:31:24 UTC.

Briefings

Guinea-Bissau terminated a planned newborn hepatitis B vaccine trial after ethical concerns emerged regarding its US funding and potential exploitation of local populations. The decision follows weeks of negotiation between local authorities and international partners, marking a significant shift in the country's public health strategy. This cancellation represents a major setback for the trial's objectives and highlights ongoing tensions in global health initiatives involving vulnerable communities.

Key points

• Guinea-Bissau cancelled a proposed newborn hepatitis B vaccine trial following ethical criticism of its US funding model.
• The trial was suspended after weeks of negotiation between local authorities and international partners.

Context

This decision marks a significant shift in Guinea-Bissau's public health strategy following weeks of negotiation between local authorities and international partners regarding a controversial US-funded vaccine trial.

Limitations

Evidence is limited to the announcement of the cancellation; specific dates of the trial, number of affected newborns, and reasons for ethical concerns remain unconfirmed.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 06/11/2026, 13:19:13 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeicd75iunjohfqpuriweowvexkmcrjdkc7dutytr5a6fhlr7fdm3r4